Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033)
NCT04776252
·
clinicaltrials.gov ↗
PHASE3
Phase
ACTIVE_NOT_RECRUITING
Status
2000
Enrollment
INDUSTRY
Sponsor class
Conditions
HIV-1 Infection
Interventions
DRUG:
MK-8591A
Sponsor
Merck Sharp & Dohme LLC